CLOs on the Move

Stevanato Group

www.stevanatogroup.com

 
Founded in 1949, Stevanato Group is committed to create systems, processes and services that guarantee the integrity of parenteral medicines. It is comprised of two operational divisions: Pharmaceutical Systems (Ompi and Balda brands): specialized in ready-to-use glass containers and bulk primary packaging (syringes, cartridges, vials, and ampoules); high quality and high precision plastic solutions for diagnostic, pharmaceutical and medical device applications. Engineering Systems (Spami, Optrel, InnoScan and SVM brands): specialized in glass forming technology, inspection systems, assembly, packaging machines and serialization solutions for the pharmaceutical industry. These two divisions enjoy a close, synchronous relationship, featuring daily exchanges which ensure that Stevanato Group ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Cary Pharmaceuticals Inc

Cary Pharmaceuticals Inc is a Great Falls, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vancouver Clinic

Vancouver Clinic has medical clinics, urgent care facilities, highly rated doctors and laboratories. Located in Southwest Washington.

BioScrip

BioScrip is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Harvard Drug Group

The Harvard Drug Group is a Livonia, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx`s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.